Extended Data Fig. 8: PDX trial of FGFR and KIT combination therapy in SDH-deficient GIST.
From: Altered chromosomal topology drives oncogenic programs in SDH-deficient GISTs
a, b, Genomic views depict RNA expression (black), H3K27ac (green) and CTCF occupancy (orange) over the FGF (a) and KIT (b) loci for the S1 primary tumour and PDX. Genes (blue), super-enhancers (green bar and shade) and lost CTCF insulators (orange shade) are indicated. c, Plot depicts tumour volume during treatment and observation periods of experiment, as in Fig. 4g, except with time axis extended until final group reached censor point (one tumour in the group >2,000 mm3). Points represent mean tumour size, error bars represent s.e.m., and shading represents range of tumour sizes for n = 8 biologically independent xenograft-bearing mice per group. For statistics, see Fig. 4g. d, Kaplan–Meier plot depicts survival until clinical endpoint (tumour size >2,000 mm3) for the same PDX trial. Median and range survival are indicated for each group. P values reflect difference in survival between groups as calculated by logrank test.
